SINTILIMAB
Clinical trials for SINTILIMAB explained in plain language.
Never miss a new study
Get alerted when new SINTILIMAB trials appear
Sign up with your email to follow new studies for SINTILIMAB, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for brain cancer: Triple-Drug cocktail targets tough lymphoma
Disease control Recruiting nowThis study tests a combination of three drugs (thiotepa, pirtobrutinib, and sintilimab) in 24 people with a hard-to-treat brain lymphoma that has come back or not responded to prior treatment. The goal is to see if this approach can shrink tumors and improve survival. Participant…
Matched conditions: SINTILIMAB
Phase: PHASE2 • Sponsor: Zhejiang Cancer Hospital • Aim: Disease control
Last updated May 26, 2026 03:59 UTC
-
New drug combo before surgery shows promise for tough liver cancers
Disease control Recruiting nowThis study is testing whether giving two drugs (sintilimab and bevacizumab) before surgery can help prevent liver cancer from coming back in people whose cancer has spread beyond the usual Milan criteria. About 37 adults with resectable liver cancer will receive the drug combinat…
Matched conditions: SINTILIMAB
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated May 26, 2026 03:58 UTC
-
New 4-Drug cocktail takes on deadly colorectal cancer
Disease control Recruiting nowThis study tests a combination of four drugs (sintilimab, ipilimumab, cetuximab, and dabrafenib) in people with a specific, hard-to-treat type of colorectal cancer that has spread. The cancer must have a BRAF V600E mutation and be microsatellite stable (MSS). The goal is to see i…
Matched conditions: SINTILIMAB
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated May 19, 2026 12:01 UTC
-
New lung cancer combo shows promise in early trial
Disease control Recruiting nowThis study tests whether adding the drug sintilimab to standard chemotherapy and a personalized radiation plan can help control stage III non-small cell lung cancer. About 35 adults aged 18-75 who cannot have surgery will receive the combination. The main goal is to see how long …
Matched conditions: SINTILIMAB
Phase: PHASE2 • Sponsor: The Third Xiangya Hospital of Central South University • Aim: Disease control
Last updated May 14, 2026 12:03 UTC